Close Menu

Breaking News

The consortium plans to develop recommendations on the best practices for implementing clinical whole-genome sequencing for rare genetic disease diagnosis.

The NGS assay is designed to help physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies.

The German firm said that researchers can now run its GynTect cervical cancer assay on Roche Diagnostics' Cobas z 480 analyzer.

The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.

Danaher has commenced its concurrent offerings of $1.35 billion of shares of its common stock and $1.35 billion of shares of its mandatory convertible preferred stock.

The two genome-wide association studies of chronic obstructive pulmonary disease uncovered numerous novel risk variants, including ones in genes involved in ciliogenesis and lung development.

The company posted $25.8 million in revenues for the quarter, up from $19.6 million a year ago, as total genomic test volume grew 28 percent to 9,154 tests.

Researchers assembled a near chromosome-level genome for the cultivated octoploid strawberry, uncovering the plant's diploid progenitors and sub-genome interactions.

The funding will be used to develop a platform to identify species and strains of bacteria that cannot be cultured or detected with standard methods.

Using data for more than a million individuals with or without insomnia, two independent research teams tracked down associated risk loci and explored their functional effects.

Researchers used a genome-wide association study to identify seven loci associated with ASD and other conditions, along with five loci linked to ASD alone.

The company signed distribution agreements covering 15 countries for its PlexWell technology and products for multiplexed NGS applications.

Danaher is financing the deal with $3 billion from an equity offering, cash on hand, and proceeds from an issuance of debt and/or new credit facilities.

The deals cover the Finnish diagnostic company's Amplidiag and Novodiag lines of infectious disease and antibiotic resistance testing products.

Last week, GenomeWeb's readers were most interested in Icon's acquisition of MolecularMD for an undisclosed amount.

Using RNA sequence data from the Cancer Genome Atlas and the Chinese Glioma Genome Atlas, researchers identified six genes with expression ties to overall survival.

Last month, the company announced two transactions that it said would enable it to regain compliance with the Nasdaq's listing requirement.

These loci include a known asthma locus at 17q12-q21, but also loci at 8p23 and 8q24 that could be specific to asthma risk among individuals of African ancestry.

The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.

The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.

With Hi-C mapping, FISH imaging insights, and other approaches, researchers identified genome organization plasticity and between-allele variability.

MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment.

Pages

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.